CervoMedCRVO
CRVO
About: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Employees: 15
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
504% more capital invested
Capital invested by funds: $3.46M [Q4 2024] → $20.9M (+$17.4M) [Q1 2025]
8.24% more ownership
Funds ownership: 18.01% [Q4 2024] → 26.24% (+8.24%) [Q1 2025]
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2% less funds holding
Funds holding: 46 [Q4 2024] → 45 (-1) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
40%
upside
Avg. target
$16.50
132%
upside
High target
$21
195%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 40%upside $10 | Buy Maintained | 11 Jun 2025 |
Chardan Capital Daniil Gataulin | 111%upside $15 | Buy Maintained | 12 May 2025 |
Roth MKM Boobalan Pachaiyappan | 181%upside $20 | Buy Maintained | 18 Mar 2025 |
Canaccord Genuity Sumant Kulkarni | 195%upside $21 | Buy Maintained | 18 Mar 2025 |
Financial journalist opinion
Negative
Zacks Investment Research
1 month ago
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
Positive
Seeking Alpha
2 months ago
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Neutral
GlobeNewsWire
2 months ago
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
Positive
Seeking Alpha
2 months ago
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.
Neutral
GlobeNewsWire
3 months ago
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p
Neutral
GlobeNewsWire
4 months ago
CervoMed to Present at the 8th International Lewy Body Dementia Conference
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here.
Neutral
GlobeNewsWire
6 months ago
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees.
Negative
Benzinga
6 months ago
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
On Tuesday, CervoMed Inc. CRVO stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB).
Negative
Market Watch
6 months ago
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
Charts implemented using Lightweight Charts™